Skip to main content
SpringerLink
Log in

Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.

Methods

This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.

Results

The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (P=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and iris or angle neovascularization (P=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular pressure (P=0.464), mean number of glaucoma medications (P=1.00), or presence of anterior segment neovascularization (P=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control group (P=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between the two groups (P=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required surgery (P<0.001), usually with a glaucoma drainage implant. Both bevacizumab and control patients who presented with closed angles required glaucoma surgery (P=1.000).

Conclusions

Treatment of anterior segment neovascularization with intravitreal bevacizumab significantly improves visual outcomes and significantly decreases the need for glaucoma surgery. In patients with closed anterior chamber angle, addition of bevacizumab treatment does not reduce the need for glaucoma surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502–508.

    Article  PubMed  Google Scholar 

  2. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41:614–625.

    Article  PubMed  CAS  Google Scholar 

  3. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158–160.

    Article  PubMed  CAS  Google Scholar 

  4. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054–1056.

    Article  PubMed  CAS  Google Scholar 

  5. Mason JO 3rd, Albert MA Jr., Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina. 2006;26:839–841.

    Article  PubMed  Google Scholar 

  6. Kelkar AS, Kelkar SB, Kelkar JA, Nagpal M, Patil SP. The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophtalmol. 2007;(303):43–45.

    PubMed  Google Scholar 

  7. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144–146.

    PubMed  Google Scholar 

  8. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008;28:59–61.

    Article  PubMed  Google Scholar 

  9. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009;23:117–123.

    Article  PubMed  CAS  Google Scholar 

  10. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol. 2007;35:494–496.

    Article  PubMed  Google Scholar 

  11. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354–356.

    Article  PubMed  Google Scholar 

  12. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542–1547.

    Article  PubMed  CAS  Google Scholar 

  13. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma. 2007;16:437–439.

    Article  PubMed  Google Scholar 

  14. Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol. 2007;17:269–271.

    PubMed  CAS  Google Scholar 

  15. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155–158.

    Article  PubMed  CAS  Google Scholar 

  16. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571–1580.

    Article  PubMed  Google Scholar 

  17. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008;25:438–443.

    Article  PubMed  CAS  Google Scholar 

  18. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28:696–702.

    Article  PubMed  Google Scholar 

  19. Hess DR. Retrospective studies and chart reviews. Respir Care. 2004:49:1171–1174.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA

    Alvaro P. C. Lupinacci, Jorge I. Calzada, Steve Charles & Peter A. Netland

  2. Charles Retina Institute, Memphis, Tennessee, USA

    Jorge I. Calzada, Mohammad Rafieetery & Steve Charles

Authors
  1. Alvaro P. C. Lupinacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge I. Calzada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Rafieetery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steve Charles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter A. Netland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter A. Netland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lupinacci, A.P.C., Calzada, J.I., Rafieetery, M. et al. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab. Adv Therapy 26, 208–216 (2009). https://doi.org/10.1007/s12325-009-0001-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0001-1

Keywords

Search

Navigation